Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 18;157(12):2709–2721. doi: 10.1097/j.pain.0000000000000690

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 International Association for the Study of Pain

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

PMC Copyright notice

Figure 7. — Repeated dosing of Ang-(1-7) does not affect bone remodeling of mice with established cancer-induced bone pain. (A) Representative day 14 radiographs of chronically treated animals. (B) Day 14 images were scored by 3 blinded observers with the following scale: 0, healthy bone; 1, 1 to 3 lesions; 2, 4 to 6 lesions; 3, unicortical fracture; and 4, bicortical fractures. Both saline- and Ang-(1-7)-treated cancerous animals experienced unicortical fractures. (C) Levels of carboxy-terminal collagen crosslinks (CTX) in the serum were quantified as another measure of bone remodeling. Although cancer-inoculation significantly increased (P < 0.05) CTX levels in the bone compared with both media controls. Repeated Ang-(1-7) administration did not significantly alter CTX levels compared with the 66.1 saline-treated group.